A review and recommendations on the management of psoriatic arthritis in Australia 2024

被引:0
作者
Nash, Peter [1 ,2 ,3 ]
Sumpton, Daniel [4 ]
Tellus, Michelle [5 ]
Feletar, Marie [6 ]
Bird, Paul [6 ]
Hall, Stephen [7 ,8 ]
机构
[1] Griffith Univ, Sch Med, Brisbane, Qld, Australia
[2] Rheumatol Res Unit, Sunshine Coast, Qld, Australia
[3] Univ Queensland, Dept Med, Brisbane, Qld, Australia
[4] Concord Repatriat Gen Hosp, Sydney, NSW, Australia
[5] St Vincents Private Hosp, Melbourne, Vic, Australia
[6] Univ New South Wales, Sch Clin Med, Sydney, NSW, Australia
[7] Cabrini Hosp, Melbourne Rheumatol, Melbourne, Vic, Australia
[8] Monash Univ, Monash, Vic, Australia
关键词
psoriatic arthritis; psoriatic arthritis drug therapy; pharmacotherapy; Australia; PLACEBO-CONTROLLED TRIAL; ACTIVE ANKYLOSING-SPONDYLITIS; DOUBLE-BLIND; EULAR RECOMMENDATIONS; MONOCLONAL-ANTIBODY; CERTOLIZUMAB PEGOL; PLACENTAL-TRANSFER; PRESCRIBING DRUGS; SACROILIAC JOINT; BHPR GUIDELINE;
D O I
10.1111/imj.16557
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Psoriatic arthritis (PsA) is a progressive, systemic inflammatory disease. It can lead to serious joint damage and disability, increased cardiovascular risk and reduced quality of life. Six experts met to develop the recommendations for the management of PsA in Australia. The final recommendations are approved by all panel members. Management and treatment recommendations have been made under six subheadings: Recommendations for non-steroidal anti-inflammatory drugs and glucocorticoids; Disease-modifying treatment; Screening and monitoring; Family planning; Symptom treatment and extra-articular manifestations; Comorbidities and lifestyle considerations. Our recommendations for the management of PsA in Australia draw heavily on the established global guidelines. These recommendations aim to assist clinicians to make informed, patient-centric choices when delivering treatment to people with PsA.
引用
收藏
页码:2037 / 2053
页数:17
相关论文
共 129 条
  • [1] Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates
    Alnaqbi, Khalid A.
    Hannawi, Suad
    Namas, Rajaie
    Alshehhi, Waleed
    Badsha, Humeira
    Al-Saleh, Jamal
    [J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2022, 25 (10) : 1107 - 1122
  • [2] Consensus statements for evaluation and nonpharmacological Management of Psoriatic Arthritis in UAE
    Alnaqbi, Khalid A.
    Hannawi, Saud
    Namas, Rajaie
    Alshehhi, Waleed
    Badsha, Humeira
    Al-Saleh, Jamal
    [J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2022, 25 (07) : 725 - 732
  • [3] [Anonymous], NETWORK ANZMCT AUSTR
  • [4] Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study
    Araujo, Elizabeth G.
    Englbrecht, Matthias
    Hoepken, Sabrina
    Finzel, Stephanie
    Kampylafka, Eleni
    Kleyer, Arnd
    Bayat, Sarah
    Schoenau, Verena
    Hueber, Axel
    Rech, Juergen
    Schett, Georg
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2019, 48 (04) : 632 - 637
  • [5] Australian Rheumatology Association, PRESCRIBERS INFORM M
  • [6] Australian Rheumatology Association, BIOL TARGETED SYNTHE
  • [7] Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
    Baeten, Dominique
    Sieper, Joachim
    Braun, Juergen
    Baraliakos, Xenofon
    Dougados, Maxime
    Emery, Paul
    Deodhar, Atul
    Porter, Brian
    Martin, Ruvie
    Andersson, Mats
    Mpofu, Shephard
    Richards, Hanno B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (26) : 2534 - 2548
  • [8] Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies
    Baraliakos, Xenofon
    Ranza, Roberto
    Ostor, Andrew
    Ciccia, Francesco
    Coates, Laura C.
    Rednic, Simona
    Walsh, Jessica A.
    Douglas, Kevin
    Gao, Tianming
    Kato, Koji
    Song, In-Ho
    Ganz, Fabiana
    Deodhar, Atul
    [J]. ARTHRITIS RESEARCH & THERAPY, 2023, 25 (01)
  • [9] Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
    Baraliakos, Xenofon
    Gossec, Laure
    Pournara, Effie
    Jeka, Slawomir
    Mera-Varela, Antonio
    D'Angelo, Salvatore
    Schulz, Barbara
    Rissler, Michael
    Nagar, Kriti
    Perella, Chiara
    Coates, Laura C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (05) : 582 - 590
  • [10] Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study
    Baranauskaite, Asta
    Raffayova, Helena
    Kungurov, N. V.
    Kubanova, Anna
    Venalis, Algirdas
    Helmle, Laszlo
    Srinivasan, Shankar
    Nasonov, Evgeny
    Vastesaeger, Nathan
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (04) : 541 - 548